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For the ﬁrst time, the recently published American Thoracic
Society/European Respiratory Society chronic obstructive pul-
monary disease (COPD) guidelines explicitly recognize that
“although chronic obstructive pulmonary disease . . . affects the
lungs, it also produces signiﬁcant systemic consequences” (1).
This is somewhat surprising because we have implicitly known
for many years that COPD indeed has systemic consequences.
For instance, since 1980, we have known that severe COPD can
produce signiﬁcant arterial hypoxemia (thus, presumably, some
degree of “systemic” hypoxia) and that domiciliary oxygen ther-
apy can improve survival in these patients without having any
noticeable effect on lung function (2, 3). Likewise, for more than
30 years, we have been aware of the fact that some patients with
COPD will develop weight loss and eventually cachexia (“pink
puffers”), whereas others (“blue blotters”) will not (4). The
former is clearly recognized now as a “systemic effect” of COPD
(5, 6).
So, what is really new in this ﬁeld? I believe that what is novel
is the realization that COPD is characterized by an abnormal
inﬂammatory response of the lung parenchyma to the inhalation
of particles and toxic fumes, mostly tobacco smoking (1), which
can also be detected in peripheral blood, thus qualifying it as
“systemic inﬂammation” (5, 6). We have now begun to uncover
the origin and consequences of, and seek potential therapy for,
this systemic inﬂammation in COPD, and we are beginning to
appreciate that these discoveries may be of great relevance and
lead to better management of patients with COPD (5, 6). This
presentation ﬁrst reviews the evidence supporting the presence
of systemic inﬂammation in COPD, then discusses its potential
origin and consequences, and ﬁnally, discusses potential thera-
peutic alternatives. Throughout the text, relevant questions, still
unanswered, will be identiﬁed.
SYSTEMIC INFLAMMATION IN COPD
The Evidence
Many studies have now provided convincing evidence that
COPD is associated with increased levels of several proinﬂam-
matory cytokines (e.g., tumor necrosis factor  [TNF-] and
its soluble receptors [sTNF-R55 and sTNF-R75], interleukin 6
[IL-6] and IL-8), acute phase reactants (e.g., C-reactive protein
[CRP]), oxidative stress, and activation of several inﬂammatory
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cells (e.g., neutrophils, monocytes, and lymphocytes) (5, 6). Gan
and associates recently conducted a meta-analysis encompassing
all these previous studies (7). Their conclusions are indisputable:
COPDisassociatedwithsystemicinﬂammation(7).Itisinterest-
ing to note, however, that other chronic diseases, such as heart
failure, are also characterized by systemic inﬂammation and that
their consequences in these patients are quite similar to those
seen (and discussed below) in patients with COPD (8).
Several important questions remain unanswered. First, we
do not know if all patients with COPD (or only a subgroup of
them) present with systemic inﬂammation. In other words, we
do notknow ifthe presence ofsystemicinﬂammationis adistinct
phenotypic characteristic of the disease, such as may be the
case with the presence (or absence) of pulmonary emphysema.
Second, all studies carried out so far are cross-sectional. Thus,
we do not know the quantitative and qualitative longitudinal
variation of systemic inﬂammation in a given patient. We know,
however, that systemic inﬂammation (like pulmonary inﬂamma-
tion) appears to burst during the episodes of exacerbation of
the disease (9–12). It is therefore likely that the overall level of
systemic inﬂammation changes with time and, it is hoped (see
below), with therapy.
The Origin
The origin of systemic inﬂammation in COPD is unresolved and
several potential mechanisms could be involved:
1. Tobacco smoking, the main risk factor for COPD (1), self-
induces (i.e., in the absence of COPD) systemic inﬂamma-
tion (13). In fact, this systemic inﬂammation in smokers
is believed to contribute signiﬁcantly to atherosclerosis
(14).However,whetherthepatientwithCOPDisacurrent
or ex-smoker does not seem to inﬂuence signiﬁcantly the
level of systemic inﬂammation (7). Thus, it is unlikely that
tobaccosmokingisthesolemechanismexplainingsystemic
inﬂammation in COPD.
2. An alternative explanation is that the inﬂammatory pro-
cess that occurs in the lung parenchyma of these patients
(15) “spills over” into the systemic circulation and/or
contributes to the priming and activation of different in-
ﬂammatory cells in their transit through the pulmonary
circulation (5). To explore this hypothesis, Vernooy and
collaborators (16) compared the levels of a number of
inﬂammatory markers in induced sputum (local inﬂamma-
tion) and plasma (systemic inﬂammation; Figure 1) in pa-
tients with moderate COPD and smokers with normal
lung function. These authors could not ﬁnd a signiﬁcant
relationship between the levels of these inﬂammatory
markers in the lungs and in the peripheral circulation (Ta-
ble 1) and concluded that systemic inﬂammation in COPD
was not due to an overﬂow of inﬂammatory mediators
from the local compartment and that the inﬂammatoryAgusti: Systemic Inflammation in COPD 479
Figure 1. Median values of different in-
flammatory markers determined in in-
duced sputum (left) and plasma (right)i n
patients with moderate chronic obstruc-
tive pulmonary disease (COPD; n  18)
and smokers with normal lung function
(n  17). IL  interleukin; ND  not de-
termined(belowthelowerlimitofdetect-
abilityofthemeasurement);TNFtumor
necrosis factor. * The difference between
the two groups was significant. For fur-
ther explanations, see text. Data are from
Reference 16.
responses in the local and systemic compartments are dif-
ferently regulated (16). Although this study has the merit
of being the ﬁrst to address this important topic, it has
several limitations, such as the relatively small number
of patients studied, its cross-sectional nature, the fact that
control subjects were not perfectly matched in terms of age,
sex, and smoking exposure to patients, and the observation
that many measurements were below the threshold of
detectability (16).
3. Another potential mechanism that can theoretically con-
tribute to systemic inﬂammation in COPD is tissue hyp-
oxia. To explore this, Takabatake and colleagues studied
the relationship between arterial hypoxemia and circulat-
ing levels of TNF- and its soluble receptors sTNF-R55
and sTNF-R75 in 27 patients with COPD and 15 age-
matched, healthycontrol subjects (17).TNF-, sTNF-R55,
and sTNF-R75 levels were signiﬁcantly higher in patients
with COPD, and all of them were signiﬁcantly correlated
with the severity of arterial hypoxemia. This was not ob-
servedinthehealthycontrolsubjects.Overall,theseresults
suggest that arterial hypoxemia in COPD is associated
TABLE 1. CORRELATION COEFFICIENTS AND p VALUES
AMONG THE LEVELS OF DIFFERENT INFLAMMATORY
MARKERS DETERMINED IN INDUCED SPUTUM AND PLASMA
IN 18 PATIENTS WITH CHRONIC OBSTRUCTIVE
PULMONARY DISEASE




Definition of abbreviations:I L interleukin; sTNF  soluble tumor necrosis
factor.
Data are from Reference 16. For further explanations, see text.
with activation of the TNF- system in vivo (17). If larger
studiesconﬁrmthisobservation,itisconceivablethatlong-
term oxygen therapy may contribute to reduce the burden
ofsystemic inﬂammation in thesepatients. This hypothesis
has not been tested yet,but, if proven, may well contribute
to the prolongation of survival described many years ago
in patients receiving domiciliary oxygen therapy (2, 3).
4. Skeletal musclecanbe another potentialsiteofproduction
of systemic inﬂammation, particularly during exercise, in
patients with COPD (although, as discussed below, skele-
tal muscle is also a target organ of systemic inﬂammation
in these patients [18]). Rabinovich and coworkers studied
11 patients with COPD (FEV1, 40% of predicted) and six
age-matched control subjects, and showed that moderate
exercise increases plasma TNF- levels in the former but
not in the latter (19). Other studies also support a role for
skeletal muscle as a contributor to systemic inﬂammation
in COPD (20, 21).
5. The bone marrow can also be a site of production of
systemic inﬂammation. It is know that chronic smoking
in humans causes leukocytosis and induces a number of
distinct phenotypic changes in circulating polymorphonu-
clear leukocytes that are characteristic of chronic stimula-
tionofthebonemarrow,suchasincreasedbandcellcounts
with a higher content of myeloperoxidase and enhanced
surface expression of l-selectin (13). It is also known that
cigarette smoking causes sequestration of polymorphonu-
clear leukocytes released from the bone marrow in lung
microvessels(22).Itisthereforepossiblethattheincreased
number of immature polymorphonuclear leukocytes
released by tobacco smoking contributes to the chronic
lung inﬂammation in the so-called susceptible smokers to
COPD (13). Yet, the bone marrow is a largely unexplored
area in these patients.480 PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY VOL 3 2006
The Consequences
Systemic inﬂammation can have a variety of consequences in
COPD, including weight loss, skeletal muscle atrophy and dys-
function, endothelial dysfunction and cardiovascular disease, os-
teoporosis, and depression, among others (reviewed in Refer-
ences 5 and 6). Weight loss and skeletal muscle atrophy and
dysfunction are, by far, the best characterized (18). We know
that unintendedweight loss is a poor prognostic factorin COPD,
which is responsive to therapy and is independent of the degree
of airﬂow obstruction present (23, 24). We also know that the
main cause of weight loss in COPD is skeletal muscle atrophy
(5, 6), the latter beingin part dueto apoptosis (25)and enhanced
proteolysis (26).Systemic inﬂammation andtissuehypoxialikely
contribute to these mechanisms because they are well-known
inducers of these cellular processes (27, 28).
On the other hand, systemic inﬂammation is a well-
established factor in the pathogenesis of cardiovascular disease
(14). The relationship between systemic inﬂammation and car-
diovascular disease in COPD is less well characterized, but it
is conceivable that systemic inﬂammation may contribute to
cardiovasculardiseaseinpatientswithCOPD.Arapidlygrowing
body of evidence supports this contention (reviewed in Refer-
ence 29). The relationship of systemic inﬂammation with other
so-called systemic effects of COPD, such as osteoporosis and
central nervous system abnormalities, is less well established but
certainly possible (reviewed in Reference 5).
Finally, an intriguing possibility is that systemic inﬂammation
may “feed back” to the lungs and contribute to enhance the
chronic destructive process that characterizes the disease. It is
therefore interesting tonote that inhibition ofthe vascular endo-
thelial growth factor (VEGF) receptors causes lung cell apopto-
sis and emphysema (30), that oxidative stress and apoptosis
interact and cause emphysema due to VEGF receptor blockade
(31), and that endothelial cell death and decreased expression
of VEGF and the VEGF receptor KDR/FLK-1 occur in patients
with smoking-induced emphysema(32).Thus, itis entirely possi-
ble, although not proven, that systemic oxidative stress (33), and
theincreased levelsof proinﬂammatorycytokines (mostnotably,
TNF- [34]) could also contribute to the pathogenesis of lung
damage in COPD. If the potential participation of an autoim-
mune response in the pathogenesis of COPD is ﬁnally proven
(35–38), this would also support this concept.
Potential Therapies
Quitting smoking and bronchodilator therapy form the corner-
stone of treatment in COPD (1). In severe cases, this is comple-
mented with inhaledsteroids, oxygentherapy, andrehabilitation
(1). Interestingly, many (if not all) of these “standard” therapeu-
tic options have the potential to modify systemic inﬂammation.
As discussed above, chronic smoking causes systemic inﬂamma-
tion in humans. Quitting smoking is therefore likely to reduce
this inﬂammation. The potential effect of bronchodilators on
systemic inﬂammation in COPD is less straightforward, but, by
decreasing dynamic hyperinﬂation, bronchodilators also have
the potential to reduce systemic inﬂammation (39). Inhaled ste-
roids can also contribute to this goal, as shown recently by Sin
and coworkers who demonstrated in a randomized controlled
study that withdrawal of inhaled corticosteroids increased the
baseline levels of one marker of systemic inﬂammation (CRP)
by 71%, and that 2 weeks with inhaled ﬂuticasone (500 g twice
a day) reduced CRP levels by 50% (40) (Figure 2). Because
CRP is believed to contribute to the pathogenesis of atheroscle-
rosis (41), and CRP is known to be increased in the plasma of
patients with COPD (5), these biological effects of inhaled ste-
Figure 2. Serial changes of C-reactive protein (CRP) in the three groups
studied. For further explanations, see text. Data are from Reference 40.
roids have the potential to reduce the risk of cardiovascular
disease in these patients (29). In fact, a very recent retrospective
studyseems tosupport thiscontention(42).The potentialantiin-
ﬂammatory effects of oxygen therapy and rehabilitation have
never been explored formally in patients with COPD but, be-
cause of the arguments discussed above, should be explored in
future studies. Likewise, the use of antioxidant agents, such as
N-acetyl-cysteine, is also promising and deserves further study
(43, 44). The role of more speciﬁc, antiinﬂammatory therapies
to treat systemic inﬂammation in COPD is a matter of future
research. Yet, anticytokine therapy, nuclear factor-B blockers,
and inducible nitric oxide synthase inhibitors, among others,
offer some potential, as recently reviewed (45, 46).
CONCLUSIONS
In summary, COPD can no longer be considered a disease only
of the lungs (1). It is associated with a wide variety of systemic
consequences, most notably systemic inﬂammation. A better
understanding of its origin, consequences, and potential therapy
will most likely prove to be of great relevance and lead to better
care of the patients suffering from this devastating disease.
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